Inhalon, hVIVO launch RSV human challenge trial

Inhalon Biopharma is launching a Phase 2a human challenge trial for its inhaled antiviral candidate, IN-002, aimed at treating respiratory syncytial virus (RSV). The trial, set to begin in the second half of 2026, will recruit healthy volunteers through hVIVO's FluCamp to evaluate IN-002's safety and efficacy at three dosing levels. This trial represents a shift towards at-home treatment approaches for RSV, especially beneficial for young patients. hVIVO CEO Yamin 'Mo' Khan emphasized the ongoing need for antiviral treatments despite recent vaccine approvals and noted the company's expansion in RSV challenge models. The partnership between Inhalon and hVIVO strengthens the latter’s order book and reflects the growing demand for innovative therapies in respiratory diseases. The inhaled delivery method could potentially enhance treatment comfort and efficacy for affected populations.